These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Proceedings: Tuberculosis therapy. Review on today's knowledge, developmental trends and still open problems]. Eule H; Krebs A; Iwainsky H Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):78-100. PubMed ID: 4131870 [No Abstract] [Full Text] [Related]
26. Incidence of resistance to primary and secondary antituberculosis drugs in isolates of M. tuberculosis from cases of pulmonary tuberculosis. Kothadia SN; Sengupta SR Indian J Chest Dis Allied Sci; 1984; 26(3):163-6. PubMed ID: 6443608 [No Abstract] [Full Text] [Related]
27. [Clinical significance of antitubercular agents and protein binding]. Aoyagi A Kekkaku; 1977 Mar; 52(3):101-3. PubMed ID: 859236 [No Abstract] [Full Text] [Related]
28. [Treatment of laryngeal tuberculosis (author's transl)]. Gastpar H Z Laryngol Rhinol Otol; 1973 Aug; 52(8):604-8. PubMed ID: 4741792 [No Abstract] [Full Text] [Related]
29. Therapeutic problems in the management of elderly patients with tuberculosis. Woo J; Chan HS Adverse Drug React Toxicol Rev; 1992; 11(1):13-8. PubMed ID: 1606279 [TBL] [Abstract][Full Text] [Related]
30. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs]. Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256 [No Abstract] [Full Text] [Related]
31. [Clinical pharmacology of pentazocine-diazepam anesthesia. 2. Protein binding and pharmacokinetics of diazepam (author's transl)]. Yamamoto K; Murakami S; Tsuji A Masui; 1980 Oct; 29(10):1013-9. PubMed ID: 7452900 [No Abstract] [Full Text] [Related]
32. Augmentation of hepatic uridine-diphosphate glucuronyl transferase activity by antituberculous drugs in hamsters in vivo. Constantopoulos A; Loupa H; Krikos X Cytobios; 1987; 52(210-211):185-91. PubMed ID: 3123148 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of tuberculous praevesical ureteral strictures (author's transl)]. May P; Schindler E Urologe A; 1974 Jan; 13(1):1-5. PubMed ID: 4856813 [No Abstract] [Full Text] [Related]
34. [Side effects of antituberculous drugs observed within six months after admission. Tuberculosis Research Committee, Ryoken (author's transl)]. Kekkaku; 1975 Jun; 50(6):161-7. PubMed ID: 1185917 [No Abstract] [Full Text] [Related]
35. [Histological characteristics of tuberculous cavity treated with rifampicin--a comparative study with cases treated by primary drugs (author's transl)]. Tanaka I; Iwai K Kekkaku; 1981 Jul; 56(7):355-60. PubMed ID: 7328996 [No Abstract] [Full Text] [Related]
36. [Sensitivities of atypical mycobacteria to various drugs. I. Sensitivities to antituberculous drugs (author's transl)]. Kuze F; Takeda S; Maekawa N Kekkaku; 1974 Jun; 49(6):151-6. PubMed ID: 4410839 [No Abstract] [Full Text] [Related]
37. [Pharmacokinetic parameters in relation to structure of the N-pycolyl-3,5-dimethylbenzamides (author's transl)]. Idoipe Tomás A Arch Farmacol Toxicol; 1977 Aug; 3(2):141-56. PubMed ID: 921335 [No Abstract] [Full Text] [Related]